DRAP Alerts on Fake Hexaxim Vaccine in Vial Form
The Drug Regulatory Authority of Pakistan (DRAP) has issued an urgent warning regarding counterfeit children’s vaccines labeled as Hexaxim in vial form circulating within the country. This falsified vaccine batch poses significant health risks to infants and young children.
Details of the Counterfeit Vaccine
According to DRAP, Hoechst Pakistan Limited, the official distributor of Sanofi products in Karachi, alerted the authority about a batch of Hexaxim vaccine bearing the batch number X3H421VA. This batch is suspicious as it appears in vial form, which is not a registered or approved presentation of Hexaxim in Pakistan. The vaccine, which is legitimately available only as a pre-filled syringe, protects children against six infectious diseases — diphtheria, tetanus, pertussis, hepatitis B, polio, and Haemophilus influenzae type b (Hib).
DRAP emphasized that the use of this unapproved vial formulation could lead to serious adverse health effects, including treatment failure. The authority instructed its Regulatory Field Force alongside provincial drug control units to track down and confiscate these counterfeit vaccine vials throughout Pakistan’s supply chains to prevent their further distribution.
Consumer Guidance and Regulatory Actions
To safeguard public health, DRAP has cautioned consumers against purchasing or administering the identified fake vaccine. Those who have already received the vaccine and experience any health issues are urged to seek immediate medical attention and to report such incidents to DRAP or the National Pharmacovigilance Centre. The regulatory authority further advised the public to obtain vaccines solely from licensed pharmacies or authorized vendors and to thoroughly verify the authenticity and proper storage conditions of all medical products.
A DRAP spokesperson stated, “Consumers should consult healthcare professionals if they have any doubts regarding the legitimacy of vaccines or medicines,” underlining the importance of vigilance.
Implications for Pakistan’s Healthcare Sector
This alert highlights ongoing challenges in ensuring the integrity of pharmaceutical supply chains in Pakistan, particularly concerning essential immunizations for children. Vaccines like Hexaxim are crucial in protecting newborns from multiple life-threatening illnesses, and the circulation of counterfeit versions could undermine public trust in immunization efforts, potentially jeopardizing child health outcomes nationwide.
With counterfeit vaccines entering the market, authorities face increased pressure to reinforce regulatory oversight, improve supply chain transparency, and educate consumers about safe medical practices. These measures are vital to maintaining the effectiveness of vaccination programs in Pakistan and safeguarding the well-being of future generations.
